A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile

NCT ID: NCT02702388

Last Updated: 2021-11-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 241 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-06-08
• Study Completion Date: 2020-09-10

Brief Summary

This is a multicenter, randomized, double-blind study being conducted as a postmarketing requirement to the US Food and Drug Administration (FDA) to evaluate whether there is a lower starting dosage of lenvatinib 24 mg once daily (QD) that provides comparable efficacy but has a better safety profile in participants with radioiodine-refractory differentiated thyroid cancer RR-DTC with radiographic evidence of disease progression within the prior 12 months.

Detailed Description

This study consists of 2 phases, the Prerandomization Phase and the Randomization Phase. The Prerandomization Phase will last no longer than 28 days and will include a Screening Period to establish protocol eligibility and a Baseline Period to confirm eligibility and establish disease characteristics prior to randomization and treatment.

The Randomization Phase will consist of a Treatment Period and a Follow-up Period. It will begin at the time of randomization of the first participant and will consist of 28-day blinded study treatment cycles. The data cutoff for the primary analysis will occur at the end of the Randomization Phase, which is defined as when the last participant enrolled completes the Week 24 tumor assessments or discontinues study treatment if before Week 24.

Participants on treatment at the time of data cutoff for the primary analysis will remain on blinded investigational product until the primary analysis has been completed, after which they will transition to commercial lenvatinib outside the study. The last participant's last assessment (Off-treatment visit) will be the End of Study.

Participants will be randomly assigned to treatment with 1 of 2 blinded starting dosages of lenvatinib in a 1:1 ratio to receive lenvatinib 18 mg or 24 mg orally once daily (QD). Dose reductions will occur in succession based on the previous dose level (24, 20, 14, 10, and 8 mg QD, or 18, 14, 10, 8, and 4 mg QD, respectively). Once the dose has been reduced, it may not be increased at a later date.

Conditions

Thyroid Cancer

Keywords

Lenvatinib; E7080; Iodine-131 Refractory Differentiated Thyroid Cancer; Lenvima; Phase 2; RR-DTC

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

24 mg Lenvatinib

Participants will receive 24 mg once daily (QD) as the starting dose. Dose reductions will occur in succession based on the previous dose level (24, 20, 14, 10, or 8 mg QD). To maintain blinded treatment assignment, participants will be administered study drug in the form of two 10-mg capsules and two 4-mg capsules containing either lenvatinib or placebo (total of 4 capsules) to be taken orally, at approximately the same time each morning and may be taken in a fasting state or following a meal.

Group Type: EXPERIMENTAL

Lenvatinib

Intervention Type: DRUG

Lenvatinib capsule.

Lenvatinib matching placebo

Intervention Type: DRUG

Lenvatinib matching placebo capsule.

18 mg Lenvatinib

Participants will receive 18mg QD as the starting dose. Dose reductions will occur in succession based on the previous dose level (18,14, 10, 8, or 4 mg QD). To maintain blinded treatment assignment, participants will be administered study drug in the form of two 10-mg capsules and two 4-mg capsules containing either lenvatinib or placebo (total of 4 capsules) to be taken orally, at approximately the same time each morning and may be taken in a fasting state or following a meal.

Group Type: EXPERIMENTAL

Lenvatinib

Intervention Type: DRUG

Lenvatinib capsule.

Lenvatinib matching placebo

Intervention Type: DRUG

Lenvatinib matching placebo capsule.

Interventions

Lenvatinib

Lenvatinib capsule.

Intervention Type: DRUG

Lenvatinib matching placebo

Lenvatinib matching placebo capsule.

Intervention Type: DRUG

Other Intervention Names

Lenvima; E7080

Eligibility Criteria

Inclusion Criteria

1. Participants must have histologically or cytologically confirmed diagnosis of one of the following differentiated thyroid cancer (DTC) subtypes:

1. Papillary thyroid cancer (PTC)

• Follicular variant
• Variants (including but not limited to tall cell, columnar cell, cribriform-morular, solid, oxyphil, Warthin's-like, trabecular, tumor with nodular fasciitis-like stroma, Hürthle cell variant of papillary carcinoma, poorly differentiated)

2. Follicular thyroid cancer (FTC)

• Hurthle cell
• Clear cell
• Insular

2. Measurable disease meeting the following criteria and confirmed by central radiographic review:

1. At least 1 lesion of greater than or equal to (>=)1.0 centimeter (cm) in the longest diameter for a non-lymph node or >=1.5 cm in the short-axis diameter for a lymph node that is serially measurable according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) using computed tomography/magnetic resonance imaging (CT/MRI). If there is only 1 target lesion and it is a non-lymph node, it should have a longest diameter of >=1.5 cm.

2. Lesions that have had external beam radiotherapy (EBRT) or locoregional therapies such as radiofrequency (RF) ablation must show evidence of progressive disease based on RECIST 1.1 to be deemed a target lesion.

3. Participants must show evidence of disease progression within 12 months (an additional month will be allowed to accommodate actual dates of performance of screening scans, that is, within less than or equal to <=13 months) prior to signing informed consent, according to RECIST 1.1 assessed and confirmed by central radiographic review of CT and/or MRI scans.

4. Participants must be Iodine-131 refractory/resistant as defined by at least one of the following:

1. One or more measurable lesions that do not demonstrate iodine uptake on any radioiodine scan.

2. One or more measurable lesions that have progressed according to RECIST 1.1 within 12 months (an additional month will be allowed to accommodate actual dates of performance of screening scans, ie, within ≤13 months) after Iodine-131 therapy, despite demonstration of radioiodine avidity at the time of that treatment by pre- or posttreatment scanning. These participants must not be eligible for possible curative surgery.

3. Cumulative activity of Iodine-131 of greater than (>) 600 millicurie (mCi) or 22 gigabecquerels (GBq), with the last dose administered at least 6 months prior to study entry.

5. Participants with known brain metastases who have completed whole brain radiotherapy, stereotactic radiosurgery or complete surgical resection, will be eligible if they have remained clinically stable, asymptomatic, and off steroids for one month.

6. Participants must be receiving thyroxine suppression therapy and thyroid stimulating hormone (TSH) should not be elevated (TSH should be <=5.50 micro-international units per liter [mcIU/ML]). When tolerated by the participant, thyroxine dose should be changed to achieve TSH suppression (TSH <0.50 mcIU/ML) and this dose may be changed concurrently upon starting study drug treatment.

7. All chemotherapy or radiation-related toxicities must have resolved to Grade <2 severity per Common Terminology Criteria for Adverse Events (CTCAE v4.03), except alopecia and infertility.

8. Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2.

9. Adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP ≤150/90 mmHg at Screening and no change in antihypertensive medications within 1 week prior to Cycle 1/Day 1.

10. Adequate renal function defined as calculated creatinine clearance >=30 mL/min per the Cockcroft and Gault formula.

11. Adequate bone marrow function:

1. Absolute neutrophil count (ANC) >=1500/mm^3 (>=1.5*10^3/uL)

2. Platelets >=100,000/mm^3 (>=100*10^9/L)

3. Hemoglobin >=9.0 g/dL

12. Adequate blood coagulation function as evidenced by an International Normalized Ratio (INR) <=1.5.

13. Adequate liver function:

1. Bilirubin <=1.5*upper limit of normal (ULN) except for unconjugated hyperbilirubinemia or Gilbert's syndrome.

2. Alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) <=3*ULN (<=5*ULN if participant has liver metastases). If alkaline phosphatase is >3*ULN (in absence of liver metastases) or >5*ULN (in presence of liver metastases) AND the participant also is known to have bone metastases, the liver-specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of total alkaline phosphatase.

14. Males or females age >=18 years at the time of informed consent.

15. Females must not be lactating or pregnant at Screening or Baseline (as documented by a negative beta-human chorionic gonadotropin [B-hCG] test with a minimum sensitivity of 25 IU/L or equivalent units of B-hCG. A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.

16. All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group and without other known or suspected cause) or have been sterilized surgically (ie, bilateral tubal ligation, total hysterectomy or bilateral oophorectomy, all with surgery at least 1 month before dosing).

17. Females of childbearing potential should avoid becoming pregnant and use highly effective contraception while on treatment with lenvatinib and for at least 1 month after finishing treatment. Females of childbearing potential must not have had unprotected sexual intercourse within 30 days before study entry and must agree to use a highly effective method of contraception (example, total abstinence, an intrauterine device, a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 30 days after study drug discontinuation. Females who are using hormonal contraceptives must have been on a stable dose of the same hormonal contraceptive product for at least 4 weeks before dosing and must continue to use the same contraceptive during the study and for 30 days after study drug discontinuation. Women using oral hormonal contraceptives should add a barrier method.

18. Participants must voluntarily agree to provide written informed consent.

19. Participants must be willing and able to comply with all aspects of the protocol.

Exclusion Criteria

1. Anaplastic or medullary carcinoma of the thyroid.

2. Diagnosed with meningeal carcinomatosis.

3. Two or more prior vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor (VEGFR)-targeted therapies or any ongoing treatment for RR-DTC other than TSH-suppressive thyroid hormone therapy.

4. Prior treatment with lenvatinib.

5. Participants who have received any anticancer treatment within 21 days or any investigational agent within 30 days (or 5 half-lives) prior to the first dose of study drug and should have recovered from any toxicity related to previous anticancer treatment. This does not apply to the use of TSH suppressive thyroid hormone therapy.

6. Major surgery (example, laparotomy, thoracotomy or joint replacement) within 3 weeks prior to randomization or elective surgery scheduled to be performed during the study.

7. Participants having >1+ proteinuria on urine dipstick testing will undergo 24-hour urine collection for quantitative assessment of proteinuria. Participants with urine protein >=1 g/24 h will be ineligible.

8. Gastrointestinal malabsorption or any other condition that in the opinion of the investigator might affect the absorption of study drug.

9. Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or cerebral vascular accident within 6 months of the first dose of study drug, or cardiac arrhythmia associated with hemodynamic instability.

10. Prolongation of corrected QT interval (QTc) to >480 ms as demonstrated by a repeated electrocardiogram (ECG) or a clinically significant ECG abnormality, including a marked prolonged QT/QTc interval (example, a repeated demonstration of a QTc interval >500 ms).

11. Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to the first dose of study drug.

12. Active infection (any infection requiring treatment).

13. Active malignancy (except for DTC or definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix) within the past 24 months.

14. Bleeding or thrombotic disorders.

15. Known intolerance to study drug (or any of the excipients).

16. Any medical or other condition that in the opinion of the investigator(s) would preclude the participant's participation in a clinical study.

17. Females who are pregnant or breastfeeding.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Merck Sharp & Dohme LLC

INDUSTRY

Sponsor Role: collaborator

Eisai Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Facility#1

La Jolla, California, United States

Facility #1

San Diego, California, United States

Facility #1

Torrance, California, United States

Facility #1

Washington D.C., District of Columbia, United States

Facility #1

Boston, Massachusetts, United States

Facility #2

Boston, Massachusetts, United States

Facility #1

Ann Arbor, Michigan, United States

Facility #1

Detroit, Michigan, United States

Facility#2

Morristown, New Jersey, United States

Facility#1

Summit, New Jersey, United States

Facility #1

The Bronx, New York, United States

Facility #1

Columbus, Ohio, United States

Facility #1

Portland, Oregon, United States

Facility #2

Philadelphia, Pennsylvania, United States

Facility #1

Philadelphia, Pennsylvania, United States

Facility #1

Seattle, Washington, United States

Facility #1

Darlinghurst, New South Wales, Australia

Facility #1

Saint Leonards, New South Wales, Australia

Royal Brisbane and Women's Hospital

Brisbane, Queensland, Australia

Facility#2

Chermside, Queensland, Australia

Facility #1

Herston, Queensland, Australia

Facility #1

Melbourne, Victoria, Australia

Facility #1

Nedlands, Western Australia, Australia

Facility #1

Melbourne, , Australia

Facility #1

Saint Leonards, , Australia

Facility #1

Edegem, Antwerpen, Belgium

Facility #1

Brussels, Brussels Capital, Belgium

Facility #2

Namur, , Belgium

Facility #1

Namur, , Belgium

Facility #1

Calgary, Alberta, Canada

Facility #1

Toronto, Ontario, Canada

Facility #1

Québec, , Canada

Facility #1

Odense, Region Syddanmark, Denmark

Facility #1

Strasbourg, Bas-Rhin, France

Facility #1

Caen, Calvados, France

Facility #1

Dijon, Cote-d'Or, France

Facility #1

Bordeaux, Gironde, France

Facility #1

Angers, Maine-et-Loire, France

Facility #2

Villejuif, Val-de-Marne, France

Facility #1

Villejuif, Val-de-Marne, France

Facility #2

Angers, , France

Facility #1

Bordeaux, , France

Facility #1

Caen, , France

Facility #1

Dijon, , France

Facility #2

Lyon, , France

Facility #1

Paris, , France

Facility #1

Tübingen, Baden-Wurttemberg, Germany

Facility #1

Würzburg, Bavaria, Germany

Facility #1

Hanover, Lower Saxony, Germany

Facility #1

Essen, North Rhine-Westphalia, Germany

Facility #2

Essen, North Rhine-Westphalia, Germany

Facility #1

Essen, , Germany

Facility #1

Leipzig, , Germany

Facility #1

Petah Tikva, , Israel

Facility #6

Rome, Lazio, Italy

Facility #1

Rome, Lazio, Italy

Facility #2

Rome, Lazio, Italy

Facility #3

Rome, Lazio, Italy

Facility #2

Milan, Lombardy, Italy

Facility #3

Milan, Lombardy, Italy

Facility #4

Milan, Lombardy, Italy

Facility #5

Milan, Lombardy, Italy

Facility #1

Livorno, Tuscany, Italy

Facility #1

Pisa, Tuscany, Italy

Facility #6

Milan, , Italy

Facility #7

Milan, , Italy

Facility #2

Pisa, , Italy

Facility #4

Roma, , Italy

Facility #2

Rozzano, , Italy

Facility #1

Torino, , Italy

Facility #1

Viagrande, , Italy

Facility #2

Kielce, , Poland

Facility #1

Cluj-Napoca, Cluj, Romania

Facility #1

Bucharest, , Romania

Facility #4

Saint Petersburg, Leningradskaya O, Russia

Facility #3

Moscow, , Russia

Facility #4

Moscow, , Russia

Facility #1

Moscow, , Russia

Facility #2

Moscow, , Russia

Facility #1

Obninsk, , Russia

Facility #3

Saint Petersburg, , Russia

Facility #1

Saint Petersburg, , Russia

Facility #2

Saint Petersburg, , Russia

Facility#1

Busan, , South Korea

Facility #1

Goyang-si, , South Korea

Facility #3

Seoul, , South Korea

Facility #4

Seoul, , South Korea

Facility #1

Seoul, , South Korea

Facility #2

Seoul, , South Korea

Facility #1

Barcelona, Catalonia, Spain

Facility #2

Madrid, Madrid, Communidad Delaware, Spain

Facility #1

Badalona, , Spain

Facility #2

Barcelona, , Spain

Facility #1

Madrid, , Spain

Facility #2

Madrid, , Spain

Facility #3

Madrid, , Spain

Facility #1

Málaga, , Spain

Facility #1

Gothenburg, , Sweden

Facility #1

Lund, , Sweden

Facility #1

London, City of London, United Kingdom

Facility #1

Glasgow, Glasgow City, United Kingdom

Countries

Austria; Portugal; United States; Australia; Belgium; Canada; Denmark; France; Germany; Israel; Italy; Poland; Romania; Russia; South Korea; Spain; Sweden; United Kingdom

References

Taylor MH, Leboulleux S, Panaseykin Y, Konda B, de La Fouchardiere C, Hughes BGM, Gianoukakis AG, Park YJ, Romanov I, Krzyzanowska MK, Garbinsky D, Sherif B, Pan JJ, Binder TA, Sauter N, Xie R, Brose MS. Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day. Cancer Med. 2023 Feb;12(4):4332-4342. doi: 10.1002/cam4.5308. Epub 2022 Dec 4.

Reference Type: DERIVED

PMID: 36464853 (View on PubMed)

Brose MS, Panaseykin Y, Konda B, de la Fouchardiere C, Hughes BGM, Gianoukakis AG, Joo Park Y, Romanov I, Krzyzanowska MK, Leboulleux S, Binder TA, Dutcus C, Xie R, Taylor MH. A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer. J Clin Endocrinol Metab. 2022 Feb 17;107(3):776-787. doi: 10.1210/clinem/dgab731.

Reference Type: DERIVED

PMID: 34664662 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

2014-005199-27

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

E7080-G000-211

Identifier Type: -

Identifier Source: org_study_id